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Abstract: Pain remains one of the main reasons for medical consultation worldwide: 
moderate- to severe-intensity pain occurs in 19% of adult Europeans, seriously affecting the 
quality of their social and working lives. Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are not recommended for long-term use and a careful surveillance to monitor for toxicity and 
efficacy is critical. This study aims to assess: 1) the pattern of use of NSAIDs and opioids in a 
population covered by a cloud-based pharmacovigilance surveillance system; and 2) potential 
inappropriate use. A retrospective 18-months systematic analysis on patients’ pain treatment 
was performed. The primary endpoint was evaluating the prevalence of NSAIDs and opioids 
use and the duration of therapy regimen. The secondary endpoint was to investigate the preva-
lence of NSAIDs taken for 21 consecutive days concomitant with drugs for peptic ulcer and 
gastroesophageal reflux disease (GORD) or antiplatelet drugs. The yearly cost for individual 
users of concomitant NSAIDs for more than 21 consecutive days and of GORD medications 
has been estimated. A total of 3,050 subjects with chronic pain were enrolled; 97% of them 
took NSAIDs for 21 consecutive days; about one-fourth of these users also received drugs 
for peptic ulcer and GORD (Anatomical Therapeutic Chemical code A02B). The yearly cost 
foran individual who uses NSAIDs for 21 consecutive days as well as concomitant GORD 
medications is 61.23 euros. In total, 238 subjects (8%) using NSAIDs for 21 days also received 
one antiplatelet agent. About 11% of subjects received opioids at least once and only 2% of 
them carried on the therapy for more than 90 consecutive days. In evaluating the escalation in 
dosage as a proxy of dependence risk, this study shows no dosage escalation in our cohort of 
chronic pain population - that is to say we show no risk of dependence.
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Introduction
Pain remains one of the main reasons for medical consultation worldwide: among 
primary care appointments, 22% focus on pain management.1
The first large-scale computer-assisted survey undertaken to explore the prevalence, 
severity, treatment, and impact of chronic pain (CP) in 15 European countries and Israel 
concluded that CP of moderate to severe intensity occurs in 19% of adult Europeans, 
seriously affecting the quality of their social and working lives.2 
Numerous organizations and scientific associations have made efforts to find 
solutions for this problem and to facilitate the treatment of pain. In 1986, the World 
Health Organization (WHO) presented the analgesic ladder as a framework that physi-
cians could use when developing treatment plans for cancer pain, later extended also 
to nonmalignant CP.3 The WHO analgesic ladder for the treatment of CP provides 
a three-step sequential approach for analgesic administration based on pain severity 
that has global applicability. Nonopioid analgesics/nonsteroidal anti-inflammatory 
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drugs (NSAIDs) were recommended for mild pain, with 
the addition of mild opioids for moderate pain and strong 
opioids for severe pain.
This therapeutic guideline paved the way for considerable 
improvements in the management of CP, and after 28 years 
of use, the analgesic ladder has demonstrated its effective-
ness and widespread usefulness; however, modifications are 
necessary to ensure its continued use for knowledge transfer 
in pain management.4
The European Breivik screening has shown that the most 
common medicines taken for CP were NSAIDs (44%), fol-
lowed by weak opioid analgesics (23%) and paracetamol 
(18%). Only 5% of patients were taking a strong opioid 
analgesic.2 Osteoarthritis and rheumatoid arthritis combined 
are the most common cause of pain in Europe (42%),2 but sys-
tematic reviews do not support long-term use of NSAIDs for 
these conditions.5 Also, in the USA, opioid use in older adults 
visiting clinics more than doubled between 1999 and 2010, 
and occurred across a wide range of patient characteristics 
and clinical settings.6 A recent African survey investigating 
doctors’ knowledge and attitude of treating CP demonstrated 
that only 9.5% of physicians use opioids for CP compared 
to 73% who use NSAIDs.7
NSAIDs are not recommended for long-term use, and 
a careful surveillance to monitor for toxicity and efficacy 
is critical.8 Each year in the USA, the side-effects of long-
term NSAID use cause nearly 103,000 hospitalizations and 
16,500 deaths. This figure is similar to the annual number of 
deaths from AIDS and considerably greater than the number 
of deaths from asthma and cervical cancer.9 
The risks from chronic use of NSAIDs are significant. 
They can cause life-threatening ulcers and gastrointestinal 
bleeding, a side-effect that occurs more frequently and with 
greater severity as people age.10
Epidemiological studies, open-label studies, meta-
analyses, and reviews concluded that this undesired effect of 
traditional NSAIDs also affects selective cyclooxygenase-2 
(COX-2) inhibitors, called coxibs.11 Non-aspirin NSAIDs 
may lead to a 53% increased risk for atrial fibrillation,12 
and some nonselective NSAIDs can compromise the 
cardio-preventive efficacy of aspirin, blocking the active 
site of COX-1.13 NSAIDs can worsen arterial hypertension 
to where is not controllable with drugs, and impair kidney 
function.14,15
Use of non-aspirin NSAIDs is associated with increased 
risk of non-Hodgkin lymphoma,16 and about one-third 
of people with chronic urticaria have severe reactions to 
NSAIDs, involving angioedema and anaphylaxis after their 
administration.17 NSAIDs use may mask initial pneumococcal 
pneumonia symptoms and delay antimicrobial therapy, thus 
predisposing patients to worse outcomes.18
This study aims to assess: 1) the pattern of use of pain 
medications, NSAIDs with Italian Agency of Medicines 
(AIFA) note number 66, and opioid analgesics, in a popula-
tion covered by a cloud-based pharmacovigilance surveil-
lance system; and 2) potential inappropriate use. 
Materials and methods
In this retrospective study, we performed a systematic 
analysis of patients’ pain treatment in order to detect potential 
errors in pain management. Therapy errors were identified 
through a cloud-based pharmacovigilance surveillance sys-
tem using a closed loop system that records and updates, by 
specifically designed software interfaces loaded on informa-
tion and communication technology programs, all the drugs 
taken during therapy cycles.
Subjects agreeing to participate in this pharmacovigilance 
surveillance system were followed up for the purchases 
of prescription/over the counter (OTC) medications, thus 
generating a personal pharmacologic profile. For each subject 
participating, demographic data were recorded at the enroll-
ment in the surveillance system.
Each subject was anonymously linked through an 
alphanumeric code to all prescription/OTC purchases in a 
18-month period of: NSAIDs listed in AIFA note number 
66 (AIFA note number 66 describes the active ingredient 
of drugs regarding which prescriptions should be restricted 
to a limited pathology and number of days) (Table 1); and 
(Figure 1) opioid drugs (Anatomical Therapeutic Chemical 
code [ATC] N02A). All medications were identified on the 
basis of the WHO ATC classification code. 
The prevalence of use of NSAIDs and opioid medications 
was calculated as the ratio between the number of subjects 
with at least one prescription or prescription redemption/
purchase of the medications of interest during the study 
period and the total number of subjects enrolled in the 
surveillance system. The duration of use was estimated on the 
basis of: 1) the posology recommended by the Investigator 
Medical Product Dossier (IMPD); 2) the number of units; 3) 
the number of medication packages; and 4) the number of 
refills. For NSAIDs, we defined appropriate use as use with 
a consecutive duration of 21 days.
The prevalence of patients who were overexposed 
(21 days) to NSAIDs and who had undertaken therapy with 
drugs for peptic ulcer and gastroesophageal reflux disease 
(GORD) (ATC A02B) or antiplatelet drugs (cardioaspirin, 
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Table 1 italian agency of Medicines list
International codes assigned  
by ATC classification system
Active ingredient
M01aB16 aceclofenac
M01aB01 indometacin
M01aB02 sulindac
M01aB05 diclofenac
M01aB51 indometacin, combinations
M01aB55 diclofenac, combinations
M01ac01 piroxicam
M01ac02 tenoxicam
M01ac06 meloxicam
M01ac56 meloxicam, combinations
M01ae01 ibuprofen
M01ae02 naproxen
M01ae03 ketoprofen
M01ae09 flurbiprofen
M01ae11 tiaprofenic acid
M01ae51 ibuprofen, combinations
M01ae52 naproxen and esomeprazole
M01ae53 ketoprofen, combinations
M01ah01 celecoxib
M01ah05 etoricoxib
M01aX17 nimesulide
M01aB11 acemetacin
M01ag01 mefenamic acid
M01ae49 furprofen
M01ae14 dexibuprofen
M01aB10 fentiazac
M01aX01 nabumetone
M01aB14 proglumetacin
M01ae12 oxaprozin
M01ac05 lornoxicam
M01ac01 cinnoxicam
Abbreviation: aTc, anatomical Therapeutic chemical code.
Figure 1 Prevalence.
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
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NSAID treatment time lasted for a mean duration of 
30.43 consecutive days for women and 30.37 days for men. 
About one-fourth of subjects using NSAIDs for 21 days 
also received drugs for peptic ulcer and GORD (ATC A02B). 
Among medications for peptic ulcer and GORD, the most 
used class was proton-pump inhibitors (82%; N=570). 
The yearly cost for an individual using NSAIDs for 21 
consecutive days concomitant with GORD medications is 
61.23 euros. Costs incurred until the 21st day are defined as 
appropriate and thus were not included.
In total, 238 subjects using NSAIDs for 21 days received 
also one of the following antiplatelet agents: acetylsalicylic 
acid (B01AC06), ticlopidine (B01AC05), or clopidogrel 
(B01AC04). Among these, the most used antiplatelet agent 
was acetylsalicylic acid (91%).
About 2,400 subjects, 880 men, used opioids at least once 
(Figure 1); 48 of them (2%) carried on with the therapy for 
more than 90 days consecutively. Opioid treatment lasted 
for a mean duration of 158 consecutive days for women and 
191 days for men.
Discussion
In 2010, the Italian Ministry of Health issued the Law 38 
on “Measures to ensure access to palliative care and pain 
therapy”.20 This is a highly innovative law which, for the 
first time, provides access to palliative care and pain therapy, 
defining the basic levels of care in order to ensure respect 
for dignity and health rights, equity in access to and quality 
of care, and their appropriateness with regard to the specific 
requirements. Four years after its introduction, the weak point 
remains the excessive and inappropriate use of NSAIDs in 
Italy, which have a yearly cost of over 500 million euros 
ticlopidine, clopidogrel, or prasugrel) was analyzed, matching 
prescription/purchase data in a dynamic timeline. The yearly 
cost for individual users of concomitant NSAIDs for more than 
21 consecutive days and of GORD medications was estimated. 
For opioids, posology escalation, defined as incremental 
dosage regimen, was assessed as a proxy of the risk of depen-
dence. Statistical analysis was performed using SAS© statisti-
cal package 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 3,050 subjects with CP, 62.5% aged 39–64 years 
and 65% women, were enrolled. About 2,980 subjects took 
NSAIDs for more than 21 days consecutively in 18 months 
(Figure 1) (mean age 52.4 years, 43.2% women). The con-
secutive use of NSAIDs for more than 21 days was defined as 
a potential inappropriate use by AIFA.19 The three most used 
medications were ibuprofen (27.49%), ketoprofen (15.27%), 
and diclofenac (10.67%).
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compared to less than 140 million euros per year for opioids.21 
The current systematic analysis confirms this trend: over 97% 
of the cohort used NSAIDs for 21 days consecutively, and 
this amount is even higher than the total number of subjects 
who received opioids only once.
About 8% of subjects using NSAIDs for 21 days also 
received one of the following antiplatelet agents: acetyl-
salicylic acid (B01AC06, 91%), ticlopidine (B01AC05), or 
clopidogrel (B01AC04). Antiplatelet agents should be used 
with caution in patients receiving treatment with NSAIDs, 
including COX-2 inhibitors.22
One-fourth of subjects using NSAIDs for 21 days, also 
received drugs for peptic ulcer and GORD (ATC A02B). 
Assuming that the prevalence of concomitant NSAIDs 
for more than 21 consecutive days and GORD medications 
use of 3% found in this population is similar in the general 
Italian population, with a yearly cost of 108,000.00 euros.
About 2,400 subjects used opioids at least once and 
only 2% of them carried on with the therapy for more than 
90 days consecutively. This study shows no dosage escala-
tion in our cohort of chronic pain population – that is to say 
we show no risk of dependence. While no escalation in dos-
age was highlighted, we can confidently assume that in this 
cohort, long-term opioid use (90 days) describes a proxy 
of tolerance and consequently dependence risk free for the 
period in study.
To interpret the results, it is important to highlight that 
the study population was composed of subjects participating 
in a pharmacovigilance surveillance system and not of in- or 
outpatients with CP. 
strengths
In this study, the availability of information on OTC pur-
chases allowed us to profile all pain medications. Lack of 
information on OTC use is a limitation of several studies 
assessing use of pain medications, in particular NSAIDs. 
It is important to profile all pain medications to assess 
polypharmacy.23
limitations
The study population was composed of subjects who agreed 
to participate in a pharmacovigilance surveillance system. 
These subjects may not represent the general population, 
eg, they may be more aware of the clinical relevance. The 
generalizability of results to the general population may 
therefore be limited.
The purchase of medication does not confirm with 
the actual usage of the medications, so this data could 
overestimate the results. However, by correlating the fre-
quency of medication refills and prescriptions, we can assume 
that drugs purchased were also taken. 
Disclosure
The authors report no conflicts of interest in this work.
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